|1.||Ikeda, Ken: 3 articles (02/2004 - 03/2002)|
|2.||Iwasaki, Yasuo: 3 articles (02/2004 - 03/2002)|
|3.||Ono, Satoshi: 3 articles (02/2004 - 03/2002)|
|4.||Kawazoe, Yoko: 2 articles (12/2005 - 06/2003)|
|5.||Watabe, Kazuhiko: 2 articles (12/2005 - 06/2003)|
|6.||Ichikawa, Yasumitsu: 2 articles (02/2004 - 03/2002)|
|7.||Igarashi, Osamu: 2 articles (02/2004 - 03/2002)|
|8.||Marubuchi, Shigeki: 2 articles (06/2003 - 03/2002)|
|9.||Kinoshita, Masao: 2 articles (06/2003 - 03/2002)|
|10.||Tamura, R: 2 articles (09/2001 - 07/2001)|
06/30/2000 - "Addition of both T-588 and NGF resulted in complete protection against Ca(2+) reperfusion injury. "
06/30/2000 - "T-588 at 1-10 microM partially protected astrocytes against reperfusion injury after exposure to Ca(2+)-free medium or hydrogen peroxide. "
11/01/1999 - "Several drugs including T-588 and idebenone protect astrocytes against Ca(2+)-reperfusion injury. "
06/30/2000 - "The effect of T-588 on Ca(2+) reperfusion injury including apoptosis was inhibited by the mitogen-activated protein (MAP)/extracellular signal-regulated kinase (ERK) kinase inhibitor 2'-amino-3'-methoxyflavone (PD98059), but not by the phosphoinositide 3-kinase inhibitor wortmannin. "
|2.||Facial Nerve Injuries
06/01/2003 - "We investigated whether orally administered T-588 can rescue injured motoneurons after facial nerve avulsion in adult rats. "
06/01/2003 - "These results indicate that oral administration of T-588 ameliorates the survival of injured motoneurons and supports their neuronal function after facial nerve avulsion in adult rats. "
06/01/2003 - "Oral administration of a neuroprotective compound T-588 prevents motoneuron degeneration after facial nerve avulsion in adult rats."
|3.||Alzheimer Disease (Alzheimer's Disease)
|4.||Motor Neuron Disease (Primary Lateral Sclerosis)
06/01/2003 - "T-588 may have therapeutic potential in motoneuron injury or motor neuron diseases in humans."
03/01/2002 - "Our data showing T-588 has neurotrophic action on VSCC and suggests a potential use of T-588 in treating diseases that involve degeneration and death of spinal motor neurons, such as motor neuropathy and motor neuron disease."
02/01/2004 - "Our results showing in vivo neurotrophic activity of T-588 for motor neurons support the applicability of T-588 for the treatment of motor neuron diseases, such as amyotrophic lateral sclerosis and motor neuropathies."
12/01/2005 - "These results indicate that the gene transfer of GDNF, BDNF, TGFbeta2, and GIF and oral administration of T-588 may prevent the degeneration of motoneurons in adult humans with motoneuron injury and motor neuron diseases."
|5.||Body Weight (Weight, Body)
|1.||Nerve Growth Factor (NGF)
|2.||Glial Cell Line-Derived Neurotrophic Factor (GDNF)
|3.||Brain-Derived Neurotrophic Factor (BDNF)
|5.||Hydrogen Peroxide (Hydroperoxide)